Brought to you by:

transthyretin amyloidosis

Money present
Biotech

Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug.
James Waldron Jul 22, 2026 10:01am
AstraZeneca

Hot on Alnylam's heels, AstraZeneca racks up phase 3 ATTR win

Jun 21, 2022 5:41am